Paradigm Therapeutics Ltd acquires Amedis Pharmaceuticals Ltd
New financing to accelerate drug discovery
Advertisement
Paradigm Therapeutics Ltd announced that it has completed the acquisition of Amedis Pharmaceuticals Ltd., a medicinal chemistry and drug discovery company. The transaction will create an enlarged company with a unique mix of proprietary biology and chemistry capabilities. The Company will focus on identifying highly druggable targets and novel compounds for conditions in the areas of CNS, pain, endocrinology and metabolism. It has two programmes in late stage pre-clinical development as well as a number of earlier stage programmes and opportunities. Post-merger, the Company's growth plans will see it grow by around 30% between the UK and the Singapore operations. The Company is located in Cambridge Science Park, UK and has a wholly owned subsidiary, Paradigm Therapeutics Singapore Pte Ltd., based at the Biopolis in Singapore.